The FDA handed out four authorizations this week and the most consequential wasn't a clearance at all — it was a new classification, created for AI that reads ECGs. Add Britain proposing to regulate software functions rather than whole products, and the regulatory frame is widening faster than most commercial plans account for. Also, a brain implant let someone answer a question out loud.
Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.
8 things to watch this week:
1. 🦾 A Paradromics implant let a woman with motor neuron disease answer questions out loud
Paradromics says its first Connect-One participant — a woman in her 60s who lost her speech to progressive motor neuron disease — used the company’s 400-electrode implant to choose her own words and answer open-ended questions. She was implanted in June. The feasibility study will enroll up to 10 people across the University of Michigan, Mass General and UC Davis. Cursor control was a demo. Conversation is a product, and it forces the reimbursement question nobody has answered: what is restored speech worth, and to whom.
MassDevice
2. 🫀 FDA created a device category for AI heart-attack triage
FDA granted De Novo authorization to Powerful Medical’s Queen of Hearts, an AI ECG model that flags acute coronary syndrome — including STEMI and its equivalents — for urgent cardiologist review. The company says the model has caught more than 120,000 heart attacks in Europe since CE marking, at roughly twice the sensitivity of standard care. De Novo creates the classification, not just the authorization. Every AI ECG triage tool behind this one now has a predicate to point at.
MPO
3. 🇬🇧 The UK wants to regulate AI features, not AI products
The MHRA’s National Commission into the Regulation of AI in Healthcare published 44 recommendations urging a lifecycle approach to AI-enabled devices — assess only the functions that meet the device definition rather than whole software systems, allow staged authorizations that widen as evidence accrues, and add financial penalties for non-compliance. If Britain scopes regulation to functions instead of products, US developers get a cheaper second front door — and one more divergence to manage.
GOV.UK
📋 You probably already know which part of your commercial case is weakest.
Most teams do. What’s harder is knowing what it’ll cost you at your next milestone, and what to do about it first. The free Commercial Readiness Check from RŌG Health takes two minutes and scores your case across five dimensions — buyer, evidence, economics, adoption, and capability — then tells you where you’re exposed and what to settle before you go.
Sponsored by RŌG Health
4. 🫁 Mindray is taking the ventilator business Philips walked away from
Mindray launched its SV70 non-invasive hospital ventilator in the US, built to run on Philips V60 accessories and sharing the touchscreen of its own SV900 and SV700. Philips discontinued the V60 line after recalls and will service it through December 2029; Medtronic left ventilators in 2024. Recall exits leave installed-base vacuums, and Mindray is filling this one with accessory compatibility — the cheapest switching cost a hospital can be offered.
MassDevice
5. 🧬 Mayo Clinic and Thermo Fisher are building a million-biospecimen dataset — and Mayo owns most of it
Mayo Clinic and Thermo Fisher launched Precure, LLC, majority-owned by Mayo, to link genomic, proteomic and longitudinal clinical data from one million biospecimens and find disease signals before symptoms appear. Terms weren’t disclosed. The structure is the story: a health system taking majority ownership of the data asset rather than licensing access to it. Anyone negotiating a health-system data partnership this quarter now has a harder comparable to argue against.
Mayo Clinic News Network
6. 🧠 Telix wins US approval for a brain-tumor PET agent the FDA rejected last year
FDA approved Telix’s Pixclara to distinguish recurrent or progressive glioma from treatment-related change in patients one month and older — the first FET-PET imaging drug cleared in the US, after an April 2025 rejection asking for more confirmatory evidence. Gliomas make up roughly 80% of malignant brain tumors, about 24,000 US cases a year. International guidelines already recommended FET-PET; the gap was regulatory, not clinical. A complete response letter is not a death sentence.
Fierce Biotech
7. 🔬 A robotic colonoscope cleared the FDA on a 50-patient study
Neptune Medical won 510(k) clearance for Triton 1, a robotic endoscopy system for diagnostic and therapeutic colon procedures. Its 50-patient CARE 1 study reported a 54.2% adenoma detection rate against a 35% benchmark, with no adverse events. Neptune raised $97 million in Series D in 2024, partly from Olympus. Surgical robotics fights over procedure counts in the hundreds of thousands. Screening colonoscopy is a volume business an order of magnitude larger.
MedTech Dive
8. 💉 Beta Bionics cleared a patch pump and pulled its launch forward
Beta Bionics announced FDA clearance of Mint, a reusable patch pump with a 200-unit reservoir and three-day wear plus a 12-hour grace period, alongside a next-generation dosing algorithm, 3D Intelligence, filed separately. Full US launch moves up to Q1 2027, with at least 1.5 million disposables planned for the year. Insulet’s Omnipod 5 has had the tubeless category largely to itself. It now has a same-form-factor challenger with a pharmacy-channel plan.
Beta Bionics investor relations
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.